Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Date for First Extraordinary General Meeting
Shenzhen Hepalink Pharmaceutical Group Co. Ltd. will hold its first extraordinary general meeting of 2025 on December 16 at L’Hermitage Hotel in Shenzhen. Shareholders will vote on key proposals, including the abolition of the Supervisory Committee, amendments to the Articles of Association, internal governance measures, and the election of an independent non-executive director.
Shenzhen Hepalink Pharmaceutical Group Co. Ltd. has announced that it will hold its first extraordinary general meeting of 2025 on December 16. During the meeting, shareholders will vote on several key proposals, including the proposed abolition of the Supervisory Committee, amendments to the company’s Articles of Association and related rules of procedures, amendments to certain internal corporate governance measures, and the election of an independent non-executive director. The meeting will take place at L’Hermitage Hotel in Shenzhen. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11926242), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
